Description of ALK+ NSCLC Patient Characteristics and ALK Testing Patterns.

Heather A. Wakelee,Medha Sasane,Jie Zhang,Alexander R. Macalalad,Philip J. Galebach,John Jarvis,Andrew James Kageletry,Qing Huang,Kenneth W. Culver,Eric Qiong Wu,Annie Guerin

DOI: https://doi.org/10.1200/jco.2014.32.15_suppl.8062

IF: 45.3

2014-01-01

Journal of Clinical Oncology

Abstract:8062 Background: Anaplastic lymphoma kinase (ALK) gene rearrangements are seen in 4-8% of non-small cell lung cancer (NSCLC) patients (pts). Historically these pts have been reported to be predominantly young never-smokers with adenocarcinoma histology. ALK translocations have also been more frequently reported in Asian pts. This study investigated ALK+ NSCLC pts' characteristics and physicians' ALK testing practices in the US. Methods: A panel of US community oncologists was surveyed about their ALK testing practices for NSCLC pts and key considerations and challenges encountered in ALK testing. Also, ALK+ NSCLC pts' medical charts were reviewed by the responding physicians to collect pt-level information. Results: A total of 27 physicians participated and pt-level data was collected for 273 ALK+ NSCLC pts. In this sample, ALK+ NSCLC pts were older, racially diverse, had mixed smoking histories, and 81% had adenocarcinoma. Not all pts received ALK testing upon NSCLC diagnosis; 47 (16%) pts received one systemic therapy while 7 (14%) received 2 systemic therapies prior to ALK testing. After detection of ALK rearrangements, 181 (66%) pts received crizotinib as next-line therapy, 80 (29%) received chemotherapy, and 12 (4%) did not receive further anticancer treatment. Participating physicians reported an average ALK testing rate of 67% of pts in the past 12 months. When asked about issues encountered when testing for ALK, physicians reported inadequate tissue sample (63%), delay in reporting results (41%), and inconclusive results (37%) as the top three challenges. Conclusions: In this retrospective chart review in a sample of US oncology practices, ALK+ NSCLC pts were older and racially diverse with mixed smoking histories and cancer histologies. These results challenge preconceived notions of the phenotype of ALK+ NSCLC pts. N=273 Age, mean ± SD [median] 65.1 ± 12.2 [67] N (%) Age ≥65 at primary diagnosis 152 (56) Male 142 (52) Race White 162 (59) Black or African American 49 (18) Asian 36 (13) Hispanic or Latino 22 (8) Other 4 (1) Smoking status Never smoker 90 (33) Light smoker (<10 pack-year) 91 (33) Smoker (≥10 pack-year) 89 (33) Not available 3 (1) Histology Adenocarcinoma 222 (81) Mixed 30 (11) Large cell carcinoma 13 (5) Squamous cell carcinoma 8 (3)